CSS
TLSI icon

Cubist Systematic Strategies’s TriSalus Life Sciences TLSI Stock Holding History

Cubist Systematic Strategies’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-146
Closed -$1K – 3770
2021
Q4 		$1K Buy
+146
New +$1.45K ﹤0.01% 3426

Other funds holding TLSI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cubist Systematic Strategies's TLSI Position: Q1 2022 in Review

Cubist Systematic Strategies sold out of TriSalus Life Sciences (TLSI) in Q1 2022, closing a stake of 146 shares — an estimated $1K sold.

Cubist Systematic Strategies first reported a position in TLSI in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 68 funds tracked by Wall St. Rank hold TLSI as of Q1 2022.

  • Cubist Systematic Strategies reported no remaining TriSalus Life Sciences position as of Q1 2022 after selling out during the quarter.
  • Cubist Systematic Strategies sold 146 TriSalus Life Sciences shares in Q1 2022, an estimated $1K.
  • Cubist Systematic Strategies first reported a position in TriSalus Life Sciences in Q4 2021 and held it in 1 quarter.
  • Cubist Systematic Strategies's TriSalus Life Sciences position peaked at $1K in Q4 2021.
  • 68 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q1 2022.

Based on Cubist Systematic Strategies's 13F filing for Q1 2022, filed 16 May 2022.